congestive heart failure

(redirected from Dilated cardiomyopathy)
Also found in: Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to Dilated cardiomyopathy: hypertrophic cardiomyopathy

congestive heart failure

heart′ fail`ure


n.
1. a condition in which the heart fatally ceases to function.
2. a condition in which the heart pumps inadequate amounts of blood, characterized by edema, esp. of the lower legs, and shortness of breath.
[1890–95]

con·ges·tive heart failure

(kən-jĕs′tĭv)
Inability of the heart to circulate blood adequately to the lungs and outer body tissues, resulting in weakness and shortness of breath.

congestive heart failure

Heart failure affecting either the right or left sides of the heart.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.congestive heart failure - inability to pump enough blood to avoid congestion in the tissues
coronary failure, heart failure - inability of the heart to pump enough blood to sustain normal bodily functions
References in periodicals archive ?
The DEFINITE trial, which was published in 2004, randomized 458 patients with nonischemic dilated cardiomyopathy (DCM) and a left ventricular ejection fraction of less than 36% to receive standard medical therapy alone or medical therapy plus an ICD (N.
Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with second cardial dysfunction.
Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.
Dilated cardiomyopathy caused the patient's left ventricle to swell and his heart muscles to shrink and weaken, Matsui said.
However, the prevalence, cause, and prognosis of dilated cardiomyopathy can differ according to the geographical location and sociodemographics of the affected populations.
The 44-year-old was diagnosed with dilated cardiomyopathy in 2004 and the condition is one of the main reasons people need heart transplants.
NASDAQ: ASTM), on September 19 announced that 12-month follow up data from the IMPACT-DCM clinical trial for ixmyelocel-T showed that the treatment was well-tolerated and effective in treating dilated cardiomyopathy.
1) In subSaharan Africa (SSA), dilated cardiomyopathy (DCM) accounts for 10-17% of all cardiac conditions encountered at autopsy, and for 17 48% of hospitalisations for heart failure.
There are two main forms of the disease - hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
MYK-491 is being developed in an ongoing collaboration between MyoKardia and Sanofi for the treatment of patients with dilated cardiomyopathy, or DCM.